These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29351636)

  • 1. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants.
    Wu P; Escobar GJ; Gebretsadik T; Carroll KN; Li SX; Walsh EM; Mitchel EF; Sloan C; Dupont WD; Yu C; Horner JR; Hartert TV
    Am J Epidemiol; 2018 Jul; 187(7):1490-1500. PubMed ID: 29351636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
    Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
    Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.
    Carroll KN; Gebretsadik T; Escobar GJ; Wu P; Li SX; Walsh EM; Mitchel E; Sloan CD; Dupont WD; Hartert TV
    J Allergy Clin Immunol; 2017 Jan; 139(1):66-71.e3. PubMed ID: 27212083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: a retrospective cohort study.
    Flaherman V; Li S; Ragins A; Masaquel A; Kipnis P; Escobar GJ
    Clin Ther; 2010 Dec; 32(13):2220-9. PubMed ID: 21316538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D; Schonfeld T; Amir J;
    Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus infection and immunoprophylaxis for selected high-risk children in Central Australia.
    Bolisetty S; Wheaton G; Chang AB
    Aust J Rural Health; 2005 Oct; 13(5):265-70. PubMed ID: 16171499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
    Winterstein AG; Knox CA; Kubilis P; Hampp C
    JAMA Pediatr; 2013 Dec; 167(12):1118-24. PubMed ID: 24126903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.
    Stockman LJ; Curns AT; Anderson LJ; Fischer-Langley G
    Pediatr Infect Dis J; 2012 Jan; 31(1):5-9. PubMed ID: 21817948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
    Choi Y; Meissner HC; Hampp C; Park H; Winterstein AG
    Eur J Pediatr; 2022 Feb; 181(2):841-845. PubMed ID: 34365543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
    Staebler S; Blake S
    Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
    Brault A; Pontais I; Enouf V; Debeuret C; Bloch E; Paireau J; Rameix-Welti MA; White M; Baudemont G; Lina B; Parent du Châtelet I; Casalegno JS; Vaux S; Cauchemez S
    Lancet Child Adolesc Health; 2024 Oct; 8(10):721-729. PubMed ID: 39208833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.
    Winterstein AG; Choi Y; Meissner HC
    JAMA Pediatr; 2018 Feb; 172(2):154-160. PubMed ID: 29204660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
    Winterstein AG; Eworuke E; Xu D; Schuler P
    Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations.
    Bennett MV; McLaurin K; Ambrose C; Lee HC
    PLoS One; 2018; 13(10):e0205399. PubMed ID: 30379957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023/2024 season.
    Perramon-Malavez A; de Rioja VL; Coma E; Hermosilla E; Fina F; Martínez-Marcos M; Mendioroz J; Cabezas C; Montañola-Sales C; Prats C; Soriano-Arandes A
    Eur J Pediatr; 2024 Dec; 183(12):5181-5189. PubMed ID: 39340677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
    Goldstein M; Krilov LR; Fergie J; McLaurin KK; Wade SW; Diakun D; Lenhart GM; Bloomfield A; Kong AM
    Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.